Public Company News

Long-term Follow-up Results of CARsgen's Satri-cel as Sequential Therapy After First-Line Treatment for Gastric Cancer Presented at the 2026 ASCO Annual Meeting

SHANGHAI, May 31, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the long-term analysis results of satricabtagene autoleucel ("satri-cel", CT041) (an autologous CAR T-cell product ca...

2026-06-01 08:15 2764

ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept

First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved anobjective response rate (ORR) of 81.3% and a disease control rate (DCR) of 100.0%, with consistent benef...

2026-06-01 08:15 2723

2026 ASCO | Innovent Presents Preliminary PoC Data of IBI363 (TAK-928) PD-1/IL-2α-bias bispecific fusion protein) in First-line Advanced NSCLC

* IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety in the first-line treatment of NSCLC with PD-L1 negative or low expression. The 3→1.5 mg/kg dose group (n=22) showed ORR of 86.4%, confirmed ORR (cORR) of 81.8% (95% CI: 59.7-94.8) and DCR ...

2026-06-01 08:00 2093

2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer

* After long-term follow-up, IBI363 monotherapy demonstrated strong overall survival (OS) with a long tail effect in IO-resistant squamous NSCLC and adenoNSCLC * IBI363 has entered a global Phase 3 clinical study (MarsLight-11) for IO-resistant squamous NSCLC; pending regulatory communication...

2026-06-01 08:00 2649

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session

CHICAGO, May 31, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the Company's first-in-class PD-1/VEGF bispecific antibody, has achieved a statistically significant and clinically meaningful improvement in overall survival (OS) as a first-l...

2026-05-31 21:00 2403

Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026

* Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKI * In treatment-naïve patients with advanced NSCLC without driver mutations, Golidocitinib,...

2026-05-31 08:09 3944

CLPS Incorporation Receives Nasdaq Notification Regarding Minimum Bid Price Requirements

HONG KONG, May 29, 2026 /PRNewswire/ -- CLPS Incorporation (the "Company" or "CLPS") (Nasdaq: CLPS) today announced that it received a notification letter (the "Notification Letter") from Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated May 27, 2026, indicating th...

2026-05-30 08:16 3320

Lanvin Names Barbara Werschine as CEO

SHANGHAI, May 29, 2026 /PRNewswire/ -- Lanvin Group (NYSE: LANV), a global luxury fashion group, today announced that Maison Lanvin, the oldest couture house in Paris, has appointed Barbara Werschine as Chief Executive Officer. Ms. Werschine is an accomplished leader in the international luxury s...

2026-05-29 22:29 3730

Zhongchao Inc. Announces Pricing of $5 Million Best Efforts Public Offering

SHANGHAI, May 29, 2026 /PRNewswire/ -- Zhongchao Inc. ("Zhongchao" or the "Company") (NASDAQ: ZCMD), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced the pricing of a best efforts public offering with gross proceeds ...

2026-05-29 22:00 6815

Acer Unveils Sub-1kg TravelMate P6 14 AI Business Laptop with New Acer Comfort Touch Design for Premium Luxury on the Move

Lineup also deploys new Intel Core Series 3 processors on business laptops for the first time across form factors Editor's Summary * The Acer TravelMate P6 14 AI is a Windows 11 Copilot+ PC powered by Intel Core Ultra Series 3 processors with Intel vPro, delivering 150 TOPS of platform AI pow...

2026-05-29 21:30 4885

New Acer Tablets Plus AI and AR Glasses Expand On-the-Go Capabilities

Editor's Summary * The Acer Iconia Duo S14 is a premium 14.2-inch 2.8K 3:2 OLED tablet powered by the MediaTek Dimensity 8300 SoC and Android 16, designed as the ultimate creative and productivity hub for elite professionals. * The Acer Iconia Duo S12 is a 12.2-inch 2.8K 3:2 OLED premium tabl...

2026-05-29 21:25 4492

Acer Introduces Predator Helios 18 AI: The Ultimate Gaming Laptop

Gaming lineup also includes the Acer Nitro 16 laptop, the Acer Nitro Blaze Link streaming handheld device, and accessories for leveling up gaming experiences Editor's Summary * Winner of the iF Design Award 2026, the Predator Helios 18 AI gaming laptop delivers ultimate performance with up to ...

2026-05-29 21:10 3195

Innogen to Present Phase IIb ENLIGHT Study Results for Efsubaglutide Alfa at the 2026 ADA Scientific Sessions

SHANGHAI, May 29, 2026 /PRNewswire/ -- Innogen (HKEX: 2591), a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for metabolic diseases, today announced that new clinical data from the Phase IIb ENLIGHT study of Efsubaglutide alfa in ...

2026-05-29 21:08 3904

Acer Expands Lineup of Aspire AI Copilot+ PCs With New Laptops and All-in-Ones

Editor's Summary * The Acer Aspire X 16 AI laptop includes up to the latest Intel Core Ultra X9 processors with up to 180 platform TOPS, multi-day battery life, advanced cooling, and a thin-and-light chassis. * The Acer Aspire 18 AI laptop combines the performance of Intel Core Ultra Series ...

2026-05-29 21:05 3557

Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer

* ZEGFROVY® demonstrated superior anti-tumor efficacy compared to platinum-doublet chemotherapy as a first-line treatment for advanced NSCLC with EGFR exon20ins * WU-KONG28 is the first global randomized phase 3 study with positive results for an oral, chemo-free, targeted monotherapy regimen...

2026-05-29 20:52 3310

LEIFRAS Co., Ltd. Achieves 45% Growth in After-School Day Care Network, Expanding from 20 to 29 Locations Nationwide

Expanding Developmental Support Services Through Organic Growth and Strategic M&A TOKYO, May 29, 2026 /PRNewswire/ -- LEIFRAS Co., Ltd. (Nasdaq: LFS) (the "Company" or "Leifras"), a sports and social business company dedicated to youth sports and community engagement, today announced the strateg...

2026-05-29 20:30 5947

SK bioscience Board Approves Financing Plan Supported by Korea Growth Fund

* SK bioscience's board approval follows the Financial Services Commission's May 28 announcement selecting the company as a beneficiary of the KRW 300 billion (approximately USD 230 million) Korea Growth Fund financing program * SK bioscience became the first Korean novel drug and vaccine deve...

2026-05-29 20:00 3144

RingConn Gen 3 Smart Ring Officially Launches: Expanding Long-Term Health Awareness in Everyday Life

World's Leading Provider of Cutting-Edge Smart Ring Solutions NEW YORK, May 29, 2026 /PRNewswire/ -- RingConn officially launches the Gen 3 Smart Ring globally on May 29th, bringing vascular insights and continuous tracking into a refined ultra-lightweight wearable experience. Following pre-orde...

2026-05-29 19:00 2839

ECARX and TPK to Co-Develop ORCA LiDAR Platform, an all-new LiDAR platform for global markets

* The partnership combines ECARX's system integration capabilities with TPK's optical manufacturing expertise. * Production slated for 2028 at TPK's Thailand facility. LONDON, May 29, 2026 /PRNewswire/ -- ECARX Holdings Inc. (Nasdaq: ECX) and TPK Holding Co., Ltd. (TWSE: TPK) (TPK) have signe...

2026-05-29 17:49 3467

Creality 3D Successfully Listed in Hong Kong

Debuts as Hong Kong's First Listed 3D Printing Company HONG KONG, May 29, 2026 /PRNewswire/ -- Shenzhen Creality 3D Technology Co., Ltd. (3388.HK, "Creality" or the "Company"), a global leader in consumer 3D printing, was officially listed today on the Main Board of The Stock Exchange of Hong Ko...

2026-05-29 15:00 5867
1234567 ... 766